GT199900189A - Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña. - Google Patents
Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña.Info
- Publication number
- GT199900189A GT199900189A GT199900189A GT199900189A GT199900189A GT 199900189 A GT199900189 A GT 199900189A GT 199900189 A GT199900189 A GT 199900189A GT 199900189 A GT199900189 A GT 199900189A GT 199900189 A GT199900189 A GT 199900189A
- Authority
- GT
- Guatemala
- Prior art keywords
- metoclopramide
- migraine
- treatment
- receptors agonists
- mammer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA TRATAR LA MIGRAÑA EN UN MAMIFERO, INCLUIDO EL HOMBRE, ADMINISTRANDO AL MAMIFERO UN AGONISTA DE RECEPTORES 5HT, COMBINADO CON METOCLOPRAMIDA. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN VEHICULO FARMACEUTICAMENTE ACEPTABLE, UN AGONISTA DE RECEPTORES 5HT, Y METOCLOPRAMIDA. EJEMPLOS DE RECEPTORES DE 5HT Y METOCLOPRAMIDA. SON AGONISTAS DE RECEPTORES 5HT, SON AGONISTAS DE UNO O MAS DE LOS RECEPTORES 5HTA, 5HTB C,D,E,F.. LA FORMULA GENERAL ESTA REPRESENTADA COMO FORMULA I.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10632898P | 1998-10-30 | 1998-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT199900189A true GT199900189A (es) | 2001-04-21 |
Family
ID=22310818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT199900189A GT199900189A (es) | 1998-10-30 | 1999-10-29 | Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña. |
Country Status (34)
Country | Link |
---|---|
US (2) | US6255334B1 (es) |
EP (1) | EP1126840A1 (es) |
JP (1) | JP2002528497A (es) |
KR (1) | KR20010089363A (es) |
CN (1) | CN1325304A (es) |
AP (1) | AP2001002129A0 (es) |
AR (1) | AR019246A1 (es) |
AU (1) | AU5994799A (es) |
BG (1) | BG105534A (es) |
BR (1) | BR9914901A (es) |
CA (1) | CA2348543A1 (es) |
CO (1) | CO4950530A1 (es) |
CZ (1) | CZ20011468A3 (es) |
EA (1) | EA200100284A1 (es) |
EE (1) | EE200100243A (es) |
GT (1) | GT199900189A (es) |
HK (1) | HK1040929A1 (es) |
HR (1) | HRP20010298A2 (es) |
HU (1) | HUP0104696A3 (es) |
ID (1) | ID28291A (es) |
IL (1) | IL141957A0 (es) |
IS (1) | IS5898A (es) |
MA (1) | MA26702A1 (es) |
NO (1) | NO20012013L (es) |
OA (1) | OA11669A (es) |
PA (1) | PA8484801A1 (es) |
PE (1) | PE20001284A1 (es) |
PL (1) | PL347541A1 (es) |
SK (1) | SK5522001A3 (es) |
TN (1) | TNSN99203A1 (es) |
TR (1) | TR200101174T2 (es) |
TW (1) | TW524692B (es) |
WO (1) | WO2000025778A1 (es) |
ZA (1) | ZA200103322B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0105131D0 (en) * | 2001-03-01 | 2001-04-18 | Pfizer Ltd | Compositions having improved bioavailability |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
NZ529417A (en) * | 2001-05-24 | 2006-11-30 | Alexza Pharmaceuticals Inc | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
WO2002094242A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
AU2002363947A1 (en) | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CA2507159A1 (en) | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
CA2526478A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
US20050282879A1 (en) * | 2004-06-17 | 2005-12-22 | Foad Salehani | Methods and composition for treatment of migraine and symptoms thereof |
JP5833804B2 (ja) * | 2005-04-13 | 2015-12-16 | ニューラクソン,インコーポレーテッド | Nos阻害活性を有する置換インドール化合物 |
WO2007118314A1 (en) * | 2006-04-13 | 2007-10-25 | Neuraxon, Inc. | 1,5 and 3,6- substituted indole compounds having nos inhibitory activity |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20090131503A1 (en) * | 2007-11-16 | 2009-05-21 | Annedi Subhash C | 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
EP2220075A4 (en) * | 2007-11-16 | 2012-02-29 | Neuraxon Inc | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN |
AU2008321353A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
AU2013202680C1 (en) * | 2008-04-28 | 2016-06-23 | Zogenix, Inc. | Novel formulations for treatment of migraine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
EP1024833A1 (en) * | 1996-07-11 | 2000-08-09 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
GB9709739D0 (en) | 1997-05-14 | 1997-07-02 | Merck Sharp & Dohme | Pharmaceutical formulation |
-
1999
- 1999-09-01 US US09/387,990 patent/US6255334B1/en not_active Expired - Fee Related
- 1999-10-18 EE EEP200100243A patent/EE200100243A/xx unknown
- 1999-10-18 CZ CZ20011468A patent/CZ20011468A3/cs unknown
- 1999-10-18 BR BR9914901-0A patent/BR9914901A/pt not_active IP Right Cessation
- 1999-10-18 EA EA200100284A patent/EA200100284A1/ru unknown
- 1999-10-18 PL PL99347541A patent/PL347541A1/xx not_active Application Discontinuation
- 1999-10-18 ID IDW00200100930A patent/ID28291A/id unknown
- 1999-10-18 IL IL14195799A patent/IL141957A0/xx unknown
- 1999-10-18 CA CA002348543A patent/CA2348543A1/en not_active Abandoned
- 1999-10-18 HU HU0104696A patent/HUP0104696A3/hu unknown
- 1999-10-18 OA OA1200100100A patent/OA11669A/en unknown
- 1999-10-18 AU AU59947/99A patent/AU5994799A/en not_active Abandoned
- 1999-10-18 AP APAP/P/2001/002129A patent/AP2001002129A0/en unknown
- 1999-10-18 CN CN99812756A patent/CN1325304A/zh active Pending
- 1999-10-18 EP EP99971318A patent/EP1126840A1/en not_active Withdrawn
- 1999-10-18 SK SK552-2001A patent/SK5522001A3/sk unknown
- 1999-10-18 KR KR1020017005271A patent/KR20010089363A/ko not_active Application Discontinuation
- 1999-10-18 WO PCT/IB1999/001694 patent/WO2000025778A1/en not_active Application Discontinuation
- 1999-10-18 JP JP2000579219A patent/JP2002528497A/ja active Pending
- 1999-10-18 TR TR2001/01174T patent/TR200101174T2/xx unknown
- 1999-10-27 TN TNTNSN99203A patent/TNSN99203A1/fr unknown
- 1999-10-27 MA MA25827A patent/MA26702A1/fr unknown
- 1999-10-27 TW TW088118594A patent/TW524692B/zh active
- 1999-10-27 PA PA19998484801A patent/PA8484801A1/es unknown
- 1999-10-28 AR ARP990105447A patent/AR019246A1/es not_active Application Discontinuation
- 1999-10-29 GT GT199900189A patent/GT199900189A/es unknown
- 1999-10-29 CO CO99068659A patent/CO4950530A1/es unknown
- 1999-10-29 PE PE1999001083A patent/PE20001284A1/es not_active Application Discontinuation
-
2001
- 2001-03-16 IS IS5898A patent/IS5898A/is unknown
- 2001-04-19 US US09/838,440 patent/US20010020036A1/en not_active Abandoned
- 2001-04-24 NO NO20012013A patent/NO20012013L/no not_active Application Discontinuation
- 2001-04-24 ZA ZA200103322A patent/ZA200103322B/en unknown
- 2001-04-25 HR HR20010298A patent/HRP20010298A2/hr not_active Application Discontinuation
- 2001-05-22 BG BG105534A patent/BG105534A/xx unknown
-
2002
- 2002-04-11 HK HK02102736.3A patent/HK1040929A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT199900189A (es) | Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña. | |
ECSP056097A (es) | Antagonistas del receptor cgrp | |
GT199900070A (es) | Derivados de isotiazol, utiles como agentes anticancerosos. | |
EA200400337A1 (ru) | Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства | |
ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
UY25794A1 (es) | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a | |
PA8493701A1 (es) | Compuestos para tratar la obesidad | |
BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
CO5271709A1 (es) | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
CO5251465A1 (es) | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol | |
GT199800158AA (es) | Agonistas de prostaglandinas y su uso para tratar trastornos oseos | |
UY28150A1 (es) | Agentes terapeuticos | |
PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
CR20120009A (es) | 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) | |
ES2174129T3 (es) | Antagonistas de la hormona de liberacion de la gonadotropina. | |
DOP2002000545A (es) | Moléculas pequeñas para el tratamiento del crecimiento celular anormal | |
SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
UY27800A1 (es) | Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata. | |
ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
SV2004001417A (es) | Composiciones famaceuticas y procedimientos para administrar agonistas selectivos del receptor ep2 ref. pc10465 | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica |